CiteFacts · FDA Drug Shortages · FDA source
FDA shortage status: Ifosfamide Injection
FDA source answer
FDA currently lists this ingredient in shortage.
FDA source statuses: Current. First FDA posting: 2026-06-12. Latest FDA row update: 2026-10-02.
FDA lists 8 package records, with companies: Baxter Healthcare, Baxter Healthcare Company, Baxter Healthcare Corporation, Fresenius Kabi USA, LLC, Hikma Pharmaceuticals USA Inc., Hikma Pharmaceuticals USA, Inc., SteriMax Inc., SteriMax, Inc.. Package NDCs: 0143-9530-01, 0143-9531-01, 0338-3991-01, 0338-3993-01, 10019-925-01, 10019-926-02, 21586-211-02, 63323-142-10.
FDA shortage reason: Demand increase for the drug; Requirements related to complying with good manufacturing practices
This is nationwide FDA status, not local pharmacy inventory. CiteFacts does not provide medical, treatment, substitution, or dosing advice.
FDA package and manufacturer records
| Company | Package NDC | Presentation | FDA availability field | FDA update |
|---|---|---|---|---|
| Baxter Healthcare | 0338-3991-01 | IFEX, Injection, 1 g/20 mL (NDC 0338-3991-01) | Available | 2026-10-02 |
| Baxter Healthcare | 0338-3993-01 | IFEX, Injection, 3 g/60 mL (NDC 0338-3993-01) | Unavailable | 2026-10-02 |
| Baxter Healthcare | 10019-925-01 | Ifosfamide, Injection, 1 g/20 mL (NDC 10019-925-01) | Available | 2026-10-02 |
| Baxter Healthcare | 10019-926-02 | Ifosfamide, Injection, 3 g/60 mL (NDC 10019-926-02) | Available | 2026-10-02 |
| Fresenius Kabi USA, LLC | 63323-142-10 | Ifosfamide, Injection, 1 g/1 (NDC 63323-142-10) | Limited Availability | 2026-09-15 |
| Hikma Pharmaceuticals USA, Inc. | 0143-9530-01 | Ifosfamide, Injection, 50 mg/1 mL (NDC 0143-9530-01) | Unavailable | 2026-09-18 |
| Hikma Pharmaceuticals USA, Inc. | 0143-9531-01 | Ifosfamide, Injection, 50 mg/1 mL (NDC 0143-9531-01) | Unavailable | 2026-09-18 |
| SteriMax, Inc. | 21586-211-02 | Ifosfamide, Injection, 1 g/1 (NDC 21586-211-02) | Available | 2026-09-08 |
Source facts
Grouped generic ingredient: Ifosfamide Injection · 8 package records
Therapeutic categories: Oncology, Pediatric
Dosage forms: Injection
Routes: INTRAVENOUS
Open FDA source data · JSON · Markdown
FDA is authoritative. Source retrieved 2026-10-06T18:55:41+00:00. Derived grouping is documented in this record's derivations.